Chardan Capital Markets resumed coverage of Alto Neuroscience with a rating of Buy and set a new price target of $30.00

BTIG Research initiated coverage of Alto Neuroscience with a rating of Buy

Chardan Capital Markets initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $15.00

Wedbush downgraded Alto Neuroscience from Outperform to Neutral and set a new price target of $4.00 from $29.00 previously

Rodman & Renshaw downgraded Alto Neuroscience from Buy to Neutral

Wedbush initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $29.00

William Blair initiated coverage of Alto Neuroscience with a rating of Outperform

TD Cowen initiated coverage of Alto Neuroscience with a rating of Outperform

Robert W. Baird initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $32.00

Jefferies initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $33.00

Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week, signaling a potential shift in how regulators and investors view psychedelic-based psychiatry[1]. The pathway is widening at the federal level, where the Drug Enforcement Administration raised its 2026 psilocybin production quota by 67%[2]. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), Relmada Therapeutics (NASDAQ:RLMD), Alto Neuroscience (NYSE:ANRO), and Axsome

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, March 2-5, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time: March 3, 2026, 1:50 pm EST Location: Boston, MA Jefferies 2026 Biotech on the Beach Summit, March 10-11, 2026 Format: One-on-one investor meetings Location: Miami, FL Available presentations will be accessible via a live webcast on the

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the Phase 2 proof-of-concept study are expected following completion of dosing and data analysis and are anticipated to guide future development decisions for ALTO-101. Cognitive impairment represents a core, persistent feature of schizophren

– The review provides strong scientific rationale to support Alto's drug development approach leveraging its Precision Psychiatry Platform – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience's leadership team, Patricio O'Donnell, M.D., Ph.D, and Amit Etkin, M.D., Ph.D., as well as Husseini Manji, M.D., former global head

– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effects so that patients can achieve the higher dose levels needed to realize the antidepressant benefits of pramipexole. The newly issued patent claims further stren

– Data presented demonstrate robust validation of Theta ITC as an EEG biomarker of CIAS and support its use as the primary outcome in the ongoing Phase 2 POC study of ALTO-101 – – Detailed analysis of data from the completed ALTO-203 Phase 2 proof-of-concept study demonstrates clear pharmacodynamic effects and suggests utility of ALTO-203 in indications with excessive daytime sleepiness and/or deficits in sustained attention – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations highlighting new data and analyses supporting th

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto's Board of Directors granted a new employee an option to purchase 150,000 shares of Alto's common stock. The stock option was granted under Alto's 2025 Inducement Plan as a material inducement to the individual entering employment with Alto in accordance with NYSE Listed Company Manual Rule 303A.08. The stock option has an exercise price of $12.80 which is equal to the closing price of Alto's common stock on the d

– Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression; on track to initiate Phase 2b trial in the first half of 2026 and Phase 3 trial by early 2027 – – Positive blinded pharmacokinetic (PK) analyses from ALTO-100 and ALTO-101 trials support clinical execution – – Topline data for Phase 2 trials of ALTO-101 in CIAS expected 1Q 2026 and ALTO-300 in MDD expected mid-2026 – – Closed $50 million PIPE; strong cash position of $184.2 million as of October 31 expected to fund planned operations into 2028, and through 4 upcoming clinical study readouts – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the devel

NEW YORK, Nov. 11, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Kristen Scholer delivers the pre-market update on November 11th Stocks opened slightly lower Tuesday after a strong global rally pushed the S&P 500 up 1.5% to start the week, fueled by optimism that the longest U.S. government shutdown could end soon.The Senate passed a temporary funding bill late Monday to keep most of the government running through January; the House vote is next, followed by President Trump's expected signature.Tech

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will present at the following upcoming investor conferences: Stifel 2025 Healthcare Conference, November 11-13, 2025 Format: Fireside chat and one-on-one meetings Presentation Date & Time: Wednesday, November 12 at 10:00-10:30 AM ET Location: New York, New York Jefferies London Healthcare Conference, November 17-20, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date & Time: Monday, November 17 at 3:30-3:55 P

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

3 - Alto Neuroscience, Inc. (0001999480) (Issuer)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

EFFECT - Alto Neuroscience, Inc. (0001999480) (Filer)

10-Q - Alto Neuroscience, Inc. (0001999480) (Filer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

– Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto's COO, M

– Experienced Medical and Executive Leader, Dr. Radhakrishnan served as Group SVP and Chief Medical Officer of Biogen, responsible for the Worldwide Medical function – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company's board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies. "Maha joins our Board at a pivotal moment for Alto, as we continu

– Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO-207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet Psychiatry – – ALTO-207 adds expected late-stage readout in treatment resistant depression within current cash runway; planned Phase 2b trial, designed to be a potentially pivotal study expected to initiate by mid-2026 – – Topline data expected from Phase 2 proof-of-concept (POC) trial of ALTO-101 in schizophrenia in the second half of 2025; Phase 2b topline data readouts include ALTO-300 in MDD expected mid-2026 followed by ALTO-100 in bipolar depression expected in the sec

–  Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – –  Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-r

– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

SC 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)